Halozyme Therapeutics Inc (HALO)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 50% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+73% over the past year+6
- 52-week positionIn the upper quarter of its 52-week range+18
- QualityRevenue growing 41% y/y+10
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst here is regulatory/legal, given the court order blocking Merck's Keytruda SC in Europe, with analyst price-target revisions acting as a secondary amplifier. Continuation over the next few weeks looks moderately likely but uncertain, as legal outcomes can be appealed or reversed and much of the move may already reflect the headline. Informational only — not financial advice.
- 1 Unpopular Stock That Deserves a Second Chance and 2 We Brush OffYahoo · 2026-10-13
- Halozyme Therapeutics (NASDAQ:HALO): A Decent Value Stock With Strong ProfitabilityChartMill · 2026-10-09
- JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $78Benzinga · 2026-10-08
- HALO Wins Court Order Blocking Merck's Keytruda SC in EuropeYahoo · 2026-10-08
- HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130Benzinga · 2026-10-08
Any AI summary is an interpretation of public news, not advice or a price target.